SCHEMBL6845970

SCHEMBL6845970

Clc1cccc(-n2ccc3ccc(-c4cccnc4)cc32)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 1/20 0.48
CYP11B1 P15538 6/20 0.45
CYP11B2 P19099 6/20 0.45
TDP2 O95551 1/20 0.45
CYP19A1 P11511 5/20 0.44
CYP17A1 P05093 1/20 0.44
ROCK2 O75116 1/20 0.43
PIM1 P11309 1/20 0.43
PIM3 Q86V86 1/20 0.43
FGFR1 P11362 1/20 0.43
ABL1 P00519 1/20 0.42
BCR P11274 1/20 0.42
PRKCA P17252 1/20 0.42
PRKCD Q05655 1/20 0.42
PGR P06401 1/20 0.41
KDR P35968 1/20 0.41
TEK Q02763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6845959 0.90 CYP11B1 (0.54) CYP11B1CYP11B2TDP2CYP19A1CYP17A1
SCHEMBL6846150 0.88 HTR1D (0.55) HTR1DCYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL6658140 0.84 CYP19A1 (0.55) HTR1DCYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL6657580 0.82 ROCK2 (0.48) CYP11B1CYP11B2TDP2CYP19A1CYP17A1
SCHEMBL6658742 0.82 CYP11B2 (0.57) HTR1DCYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL6846114 0.81 HTR1D (0.48) HTR1DCYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL28062496 0.81 CYP19A1 (0.56) CYP11B1CYP11B2CYP19A1
SCHEMBL6660867 0.80 MAPT (0.46) HTR1DCYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL6659322 0.80 HTR1D (0.47) HTR1DCYP11B1CYP11B2CYP19A1
SCHEMBL6844272 0.79 HTR6 (0.50) HTR1DCYP11B1CYP11B2CYP19A1CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 HTR1D 1156/4885CYP11B1 30/4885CYP11B2 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.